Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RAF1 | P04049 | 6/20 | 0.58 |
| ▸ | FLT3 | P36888 | 8/20 | 0.58 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615194 | 0.85 | MAPK14 (0.73) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20434972 | 0.85 | MAPK14 (0.73) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1013348 | 0.83 | MAPK14 (0.73) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13853030 | 0.83 | RAF1 (0.74) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13234448 | 0.82 | MAPK14 (1.00) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13234446 | 0.79 | MAPK14 (0.74) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2951112 | 0.79 | RAB9A (0.77) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13234441 | 0.79 | RAB9A (0.71) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2943933 | 0.78 | MAPK14 (0.78) | MAPK14NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13234666 | 0.78 | MAPK14 (0.78) | MAPK14NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPK14 487/4885NPC1 4525/4885RAB9A 3041/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPK14 473/4885NPC1 4249/4885RAB9A 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.